Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis.

Autor: Giampieri R; Medical Oncology, University Hospital and Polytechnic University of the Marche, Ancona Italy., Prete MD; Medical Oncology, University Hospital and Polytechnic University of the Marche, Ancona Italy., Prochilo T; Fondazione Poliambulanza Hospital, Brescia, Italy., Puzzoni M; Medical Oncology, University Hospital and University of Cagliari, Cagliari, Italy., Pusceddu V; Medical Oncology, University Hospital and University of Cagliari, Cagliari, Italy., Pani F; Endocrinology Unit, University Hospital and University of Cagliari, Cagliari, Italy., Maccaroni E; Medical Oncology, University Hospital and Polytechnic University of the Marche, Ancona Italy., Mascia R; Medical Oncology, University Hospital and University of Cagliari, Cagliari, Italy., Baleani MG; Medical Oncology, University Hospital and Polytechnic University of the Marche, Ancona Italy., Meletani T; Medical Oncology, University Hospital and Polytechnic University of the Marche, Ancona Italy., Berardi R; Medical Oncology, University Hospital and Polytechnic University of the Marche, Ancona Italy., Lanzillo AM; Medical Oncology, Azienda Ospedaliera 'Brotzu' Cagliari, Italy., Mariotti S; Endocrinology Unit, University Hospital and University of Cagliari, Cagliari, Italy., Zaniboni A; Fondazione Poliambulanza Hospital, Brescia, Italy., Cascinu S; Medical Oncology, University Hospital and University of Modena and Reggio Emilia, Modena, Italy., Scartozzi M; Medical Oncology, University Hospital and University of Cagliari, Cagliari, Italy.

Publikováno v: Scientific reports [Sci Rep] 2017 Apr 05; Vol. 7, pp. 45703. Date of Electronic Publication: 2017 Apr 05.